Nicotinic Acid and Psychiatry *

Alvarez W. C. : Editorial. Geriatrics 23: 92, 1968.

Aring C. D. , Ryder H. W. , Roseman E. , Rosenbaum M. , and Ferris E. B. : The effect of nicotinic acid and related substances on the intracranial blood flow of man. Arch. Neurol. Psychiat. 46: 649–653, 1941.

Ashby W. R. , Collins G. H. , and Bassett M. : The effects of nicotinamide and placebo on the chronic schizophrenic. J. Merit. Sci. 106: 1555–1559, 1960.

Ban T. A. : Niacin in the treatment of schizophrenias. Pharmacol. Bull. 5: 5–20, 1969.

Ban. T. A. : Nicotinic acid in the treatment of neuropsychiatrie disorders. To be presented at the Annual Meeting of Bulgarian Psychiatric Association, Sofia 1971.

Ban T. A. , and Lehmann H. E. : Nicotinic acid in the treatment of schizophrenias. Progress Report I, Canadian Mental Health Association, Toronto 1970.

Ban T. A. : Nicotinic acid in the treatment of schizophrenia. Supplementary Report A. Canadian Mental Health Association, Toronto 1971.

Bourdillon R. E. , and Ridges A. P. : Catecholamines and schizophrenia. In: Himwich H. E. (ed.): Biochemistry, Schizophrenias and Affective Illness. The Williams and Wilkins Co., Baltimore 1971.

Butcher R. W. , Baird C. E. , and Sutherland E. W. : Effect of lipolytic and anti-lipolytic substances on adenosine 3',5'-monophosphate levels in isolated fat cells. J. Biol. Chem. 243: 1705–1712, 1968.

Buscaino G. A. , Spadetta V. , and Carella A. : In vitro methylation of nicotinamide: a biochemical test for schizophrenia. In: Lopez I. (ed.): Proc. IVth Congress of Psychiatry. Excerpta Medica Foundation, Amsterdam 1966.

Cannon W. B. : Bodily changes in pain, hunger, fear and rage. R. Appleton & Co., New York 1915.

Carlson L. A. , Levi L. , and Orö L. : Plasma lipids and urinary excretion of catecholamines in man during experimentally induced emotional stress and their modification by nicotinic acid. J. Clin. Invest. 47: 1795–1805, 1968.

Carothers J. C. : The African Mind in Health and Disease. World Health Organization, Geneva 1953.

Darby W. J. : Principles of Internal Medicine. Blakiston Co., Philadelphia 1950.

deJong H. : Experimental Catatonia. The Williams and Wilkins Co., Baltimore 1945.

Denson R. : Nicotinamide in the treatment of schizophrenia. Dis. Nerv. Syst. 23: 167–172, 1962.

Ellerbrook R. C. , and Purdy M. D. : Capacity of stressed humans under mega dosages of nicotinic acid to synthesize methylated compounds. Dis. Nerv. Syst. 31(3): 196–197, 1970.

Elvehjem C. A. , Madden R. J. , Strong F. M. , and Wooley D. W. : The isolation and identification of the anti-black tongue factor. J. Biol. Chem. 123: 137–149, 1938.

Feldstein A. : Biochemical aspects of schizophrenia and antipsychotic drugs. In: DiMascio A. , and Shader R. (eds.): Clinical Handbook of Psychopharmacology. Science House, New York, 1970.

Ford F. R. : Disease of the Nervous System in Infancy, Childhood and Adolescence. Charles C. Thomas, Springfield 1952.

Fouts P. J. , Helmer O. M. , Leplovsky S. , and Jukes T. H. : The treatment of human pellagra with nicotinic acid. Proc. Soc. Exper. Biol. Med. 37: 405–407, 1937.

Friedhoff A. J. : Discussion of Stabenau et al's findings. Presented at the Annual Meeting of ACNP, San Juan, 1970.

Fujimori M. , and Alpers H. S. : Psychotomimetic compounds in man and animals. In: Himwich H. E. (ed.): Biochemistry, Schizophrenias and Affective Disorders. The Williams and Wilkins Co., Baltimore 1971.

Funk C. J. : On the chemical nature of the substance which' cures polyneuritis in birds induced by a diet of polished rice. J. Physiol. 43: 395–400, 1911.

Gallant D. M. , Bishop M. P. , and Steele C. A. : DPN (NAD-oxidized form): a preliminary evaluation in chronic schizophrenic patients. Curr. Ther. Res. 8: 542–548, 1966.

Gholson R. K. : The pyridine nucleotide cycle. Nature 212: 933–934, 1966.

Goldberger J. : Pellagra: Its Nature and Prevention. Government Printing Office, Washington 1927.

Goldstein A. , Aronow L. , and Kaiman S. M. : Principles of Drug Action. Harper & Row, New York, 1969.

Green D. E. , and Richter D. : Adrenalin and adrenochrome. Biochemical J. 31: 596–616, 1937.

Greenbaum G. H. C. : An evaluation of niacinamide in the treatment of childhood schizophrenia. Amer. J. Psychiat. 127(1): 89–92, 1970.

Greengard P. : Water soluble vitamins. In: Goodman L. S. , and Gilman A. (eds.): The Pharmacological Basis of Therapeutics. Macmillan Company, London, 1970.

Gregory I. : The role of nicotinic acid (Niacin) in mental health and disease. J. Ment. Sci. 101: 85–109, 1955.

Grollman A. , and Grollman E. F. : Pharmacology and Therapeutics. Lea and Febiger, Philadelphia, 1970.

Handler P. : Metabolism of nicotinic acid and the pyridine nucleotides. In: Umbreit W. , and Molitor H. (eds.): Vitamin Metabolism. Pergamon Press, Oxford 1960.

Harley-Mason J. : In: Osmond, H., and Smythies, J.: Schizophrenia: a new approach. J. Ment. Sci. 98: 309–315, 1952.

Harper H. A. : Review of Physiological Chemistry. Lange Medical Publication, Los Altos, 1967.

Harrell R. F. , Woodyard E. R. , and Gates A. I. : The influence of vitamin supplementation of the diets of pregnant and lactating women on the intelligence of their offspring. Metabolism 5(5): 555–562, 1956.

Hedlund S. , Köhler V. , Nylin G. Cerebral blood circulation in dementia. Acta Psychiat. Scand. 40: 77–100, 1964.

Heller B. , Narasimhachari N. , Spaide J. , Haskovec L. , and Himwich H. E. : N-dimethylated indoleamines in blood of acute schizophrenics. Experientia 26(5): 503–504, 1970.

Heyck H. : Der Einfluss der Nikotinsaure auf die Hirndurchblutung und den Hirnstoff bei Cerebral Sklerosen und anderen diffusen Durchblutungsstörungen des Gehirns. (Quantitative Messungen mittels der Stickoxydulmethode). Schweizerische Medizinische Wochenschrift 92: 226–231, 1962.

Himwich H. E. (ed.): Biochemistry, Schizophrenias and Affective Illnesses. The Williams and Wilkins Co., Baltimore, 1971.

Himwich H. E. : Indoleamines and the schizophrenias. In: Himwich H. E. (ed.): Biochemistry, Schizophrenias and Affective Illness. The Williams and Wilkins Co., Baltimore, 1971.

Hoffer A. : Biochemistry of nicotinic acid and nicotinamide. Psychosomatics 8: 95–100, 1967.

Hoffer A. : CMHA Supported Controlled Study on Psychiatrically Sick Children. Presented at the Annual Meeting of the Saskatchewan Division of the CMHA, Regina, June 1970.

Hoffer A. , Osmond H. , and Smythies J. : Schizophrenia: a new approach. J. Ment. Sci. 100: 29–54, 1954.

Hoffer A. , and Kenyon M. : Conversion of adrenalin to adrenolutin in human blood serum. A.M.A. Arch. Neurol. Psychiat 77: 437–438, 1957.

Hoffer A. : Adrenochrome in blood plasma. Amer. J. Psychiat. 114: 752–753, 1958.

Hoffer A. : The adrenochrome theory of schizophrenia: a review. Dis. Nerv. Syst. 25: 173–178, 1964.

Hoffer A. : Enzymiology of hallucinogens. Int. J. Neuropsychiat. 2: 43, 1965.

Hoffer A. : Niacin Therapy in Psychiatry. Charles C. Thomas, Springfield, 1962.

Hoffer A. : Enzymology of hallucinogens. In: Martin G. J. , and Kisch B. (eds.): Enzymes in Mental Health. Lippincott, Philadelphia, 1966.

Hollister L. E. : Drug-induced psychoses and schizophrenic reactions: a critical comparison. Ann. New York Acad. Sci. 96: 80–92, 1962.

Israelstam D. M. , Sargent T. , Finley N. N. , Winchell H. E. , Fish M. , Motto J. , Pollycove M. , and Johnson A. : Abnormal methionine metabolism in schizophrenic and depressive states: a preliminary report. J. Psychiat. Res. 7: 185–190, 1970.

Joliffe N. , Bowman K. M. , Rosenblum L. A. , and Fein H. D. : Nicotinic acid deficiency encephalopathy. J. Amer. Med. Ass. 114: 307–312, 1940.

Kanig K. : Die Bedentung der B-Vitamine für das Nerven system. E. Merck, A. G., Darmstadt, 1968.

Kassay G. , and Pinter Anna : A method to overcome therapeutic resistance to neuroleptic drugs in chronic schizophrenic patients. Arzn. Forsch 19(3a): 480–482, 1969.

Kety S. S. : Current biochemical approaches to schizophrenia. New Engl. J. Med. 276: 321, 1967.

Kety S. S. : Human cerebral blood flow oxygen consumption as related to aging. In: Moore J. E. (ed.): The Neurologic and Psychiatric Aspects of the Disorders of Aging. The Williams and Wilkins Co., Baltimore, 1956.

Kline N. S. , Barclay G. L. , Cole J. O. , Esser A. H. , Lehmann H. E. , and Wittenborn Jr. : Controlled evaluation of nicotinamide adenine dinucleotide in the treatment of chronic schizophrenic patients. Brit. J. Psychol. 113: 731–742, 1967.

Lehmann H. E. : Post-traumatic confusional state treated with massive doses of nicotinic acid. Canad. Med. Ass. J. 51: 558, 1944.

Lehmann H. E. : Niacin therapy in psychotic states:, In: Cobb, S. (Intr.): The Biology of Mental Health and Disease. Paul Hoeber Inc., New York, 1952.

Lehmann H. E. , and Ban T. A. : Pharmacological load tests as predictors of pharmacotherapeutic response in geriatric patients. In: Wittenborn J. R. , Goldberg S. C. , and May P. R. A. (eds.): Psychopharmacology and the Individual Patients. Raven Press, New York, 1970.

Lehmann H. E. , Ban T. A. , and Saxena B. M. : Nicotinic acid, thioridazine, fluoxymesterone and their combination in hospitalized geriatric patients — a systematic clinical study. Presented at the Annual Meeting of the Canadian Psychiatric Association, Halifax, Nova Scotia, June 9–12, 1971.

Loman J. , Rinkel M. , and Myerson A. : Intracranial and peripheral vascular effects of nicotinic acid. Amer. J. Med. Sci. 202: 211–216, 1941.

Maslowski J. : Zastosowanie Kwasu nikotynowego w leczeniu schizofrenii przewleklej. Psychiat. Pol. 1: 307–311, 1967.

Medlicott R. W. : Nicotinic acid in treatment of some psychiatric syndromes. New Zealand Med. J. 44: 28–33, 1945.

Meltzer H. , Shader R. , and Grinspoon L. : The behavioral effects of nicotinamide adenine dinucleotide in chronic schizophrenia. Psychophaimacologia (Berl.) 15: 144–152, 1969.

Nichols R. E. , Sugarman A. , and Murphree H. B. : Effects of nicotinamide adenine dinucleotide (NAD) and its precursors on whole blood NAD levels and on the quantitative electroencephalogram (EEG). Fed. Proc. 26: 505, 1967.

Noteboom L. : Experimental catatonia by means of derivatives of mescaline and adrenalin. Proc. Acad. Sci. 37: 562–574, 1934.

O'Reilly P. O. : Nicotinic acid therapy and the chronic schizophrenic. Dis. Nerv. Syst. 16: 67–72, 1955.

Osmond H. , and Smythies J. R. : Schizophrenia: a new approach. J. Ment. Sci. 98: 309–315, 1952.

Osmond H. , and Hoffer A. : Massive niacin treatment in schizophrenia. Review of of a nine-year study. Lancet 1: 316–319, 1962.

Paul M. I. , Ditzion B. P. , Pauk G. L. , and Janowsky D. S. : Urinary adenosine 3',5'-monophosphate excretion in affective disorders. Amer. J. Psychiat. 126(10): 1493–1497, 1970.

Pauling L. : Orthomolecular Psychiatry. Science 160: 265–271, 1968.

Preiss J. , and Handler P. : Biosynthesis of diphosphopyridine nucleotide. II. Enzymetic aspects. J. Biol. Chem. 233: 493–500, 1952.

Quinn G. P. , and Greengard P. : The pathway for the biosynthesis of N'-methyl-4-pyridone-3-carboxamide. Arch. Biochem. Biophys. 115: 146–156, 1966.

Saarma J. , and Vasar H. : Nicotinic acid as an adjuvant in the treatment of chronic schizophrenic patients with special reference to changes in higher nervous activity. Curr. Therap. Res. 12(11): 729–733, 1970.

Scheinberg P. : Effect of nicotinic acid on cerebral circulation with observations on extracerebral contamination of cerebral venous blood in nitrous oxide procedure for cerebral blood flow. Circulation 1: 1148–1154, 1950.

Schou M. : Experiences with fluorometric method for determination of pyridine nucleotides in blood, with sane determinations on blood from psychiatric patients. Biochim. et Biophys. Acta. 4: 422–426, 1950.

Sehdev H. S. : Nicotinic acid in the treatment of schizophrenic reactions. In: Behavioral Science in Progress. Reference No. 20038. American Psychological Association 1970.

Smith D. T. , Ruffin J. M. , and Smith S. G. : Pellagra successfully treated with nicotinic acid: a case report. J. Amer. Med. Ass. 109: 2054–2055, 1937.

Smith M. E. , and Newman H. W. : The rate of ethanol metabolism in fed and fasting animals. J. Biol. Chem. 234: 1544–1549, 1959.

Smythies J. R. : introduction. In: Himwich H. E. , Kety S. S. , and Smythies J. R. (eds.): Amines and Schizophrenia. Pergamon Press, Oxford, 1967.

Snezhevsky A. V. , and Vartanyan M. : The forms of schizophrenia and their biological correlates. In: Himwich H. E. (ed.): Biochemistry, Schizophrenias and Affective Illness. The Williams and Wilkins Co., Baltimore, 1971.

Spies T. D. , Cooper C. , and Blankenhom M. A. : Use of nicotinic acid in treatment of pellagra. J. Amer. Med. Ass. 110: 622–627, 1938.

Spies T. D. , and Butt H. R. : Diseases of Metabolism. W. B. Saunders Co., Philadelphia, 1952.

Stabenau J. R. , Creveling C. R. , and Daly J. : The “pink spot”, 3,4-dimethoxy-phenylethylamine, common tea and schizophrenia. Amer. J. Psychiat. 127(5): 611–616, 1970.

Stecher P. G. (ed.): The Merck Index: of Chemicals and Drugs. Merck & Co. Inc., Rahway, 1960.

Tanimukai H. , Ginther R. , Spaide J. , Bueno J. R. , and Himwich H. E. : Detection of psychotomimetic N,N-dimethylated indoleamines in the urine of four schizophrenic patients. Brit. J. Psychiat. 117: 421–430, 1970.

Thompson L. J. , and Proctor R. C. : Depressive and anxiety reactions treated with nicotinic acid and phenobarbital. North Carolina Med. J. 14: 420–426, 1953.

Warburg O. : Iron, the oxygen-carrier of respiration ferment. Science 61: 575–582, 1925.

Washburne A. C. : Nicotinic acid in treatment of certain depressed states: preliminary report. Ann. Int. Med. 32: 261–269, 1950.

Westeifeld W. W. : The intermediary metabolism of alcohol. Amer. J. Clin. Nutr. 9: 426–431, 1961.

Williams R. J. , Biochemical Individuality. John Wiley & Sons, New York, 1956.

Youmans J. B. : Handbook of Nutrition. Blakiston Co., Philadelphia, 1951.